GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Tadalafil - TADLIQ PAH oral suspension

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug2 sources available - open source summaries, references and comparisons

TADLIQ / TADLIQ PAH / tadalafil oral suspension

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

PAH scope and an unassigned exact CrCl boundary

The source uses PAH-specific daily instructions and leaves an exact boundary unstated in its numeric dosage bands.

Before applying: Do not insert an ED schedule or silently interpolate the boundary. Obtain product-specific clarification.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

DailyMed / TADLIQ exact label

Product / population
TADLIQ oral suspension for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.
Renal measure
CrCl, mL/min; exact 30 mL/min is not assigned in the printed dosage bands

Selected sections only. Source mirror and underlying label are not independent confirmations.

Renal dosing, restrictions and evidence limits

For PAH, the source starts patients with CrCl 51-80 or 31-50 mL/min at 20 mg once daily, with an increase to 40 mg once daily according to tolerability. Severe impairment is an avoidance setting; the dosage section prints CrCl <30 mL/min and hemodialysis, and the renal-use section advises avoidance in severe impairment. Dialysis does not meaningfully correct exposure.

The printed bands do not assign exactly 30 mL/min. No boundary is filled in here. These are PAH instructions, not an as-needed erectile-dysfunction schedule. The suspension is 20 mg/5 mL: the source lists 5 mL for 20 mg and 10 mL for 40 mg.

Source revision: 10/2022 | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a909b25-3772-403e-a5fe-e4a040293fb7

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

DailyMed / TADLIQ exact label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

TADLIQ oral suspension for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.

Renal method: CrCl, mL/min; exact 30 mL/min is not assigned in the printed dosage bands
Retrieved: 2026-09-09

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - TADLIQ

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

TADLIQ oral suspension for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.

Renal method: CrCl, mL/min; exact 30 mL/min is not assigned in the printed dosage bands
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

PAH scope and an unassigned exact CrCl boundary

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

boundary and indication

PAH scope and an unassigned exact CrCl boundary

The source uses PAH-specific daily instructions and leaves an exact boundary unstated in its numeric dosage bands.

How to use this: Do not insert an ED schedule or silently interpolate the boundary. Obtain product-specific clarification.

GlobalRPh RX List - TADLIQDailyMed / TADLIQ exact labelTadalafil - ADCIRCA PAH tabletsTadalafil - as-needed erectile dysfunction

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDailyMed / TADLIQ exact labelGlobalRPh RX List - TADLIQ
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/tadliq-drug/

Exact product and population

TADLIQ oral suspension for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.

RDM54-SCOPE-tadalafil-tadliq-pah · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

DailyMed / TADLIQ exact label

Open original reference

Open / share this exact local source

DailyMed / CMP Pharma, Inc. · TADLIQ oral suspension for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.

Renal method: CrCl, mL/min; exact 30 mL/min is not assigned in the printed dosage bands
Source date: 10/2022
Retrieved: 2026-09-09

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For PAH, the source starts patients with CrCl 51-80 or 31-50 mL/min at 20 mg once daily, with an increase to 40 mg once daily according to tolerability. Severe impairment is an avoidance setting; the dosage section prints CrCl <30 mL/min and hemodialysis, and the renal-use section advises avoidance in severe impairment. Dialysis does not meaningfully correct exposure.

The printed bands do not assign exactly 30 mL/min. No boundary is filled in here. These are PAH instructions, not an as-needed erectile-dysfunction schedule. The suspension is 20 mg/5 mL: the source lists 5 mL for 20 mg and 10 mL for 40 mg.

RDM54-official-tadalafil-tadliq-pah-f2de211e8e-C1 · Source locator: Sections 2.2, 3, 8.6 and 12.3

Source-specific limits

Selected sections only. Source mirror and underlying label are not independent confirmations.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a909b25-3772-403e-a5fe-e4a040293fb7
Retrieved
2026-09-09
Exact label title
TADLIQ - tadalafil suspension
DailyMed Set ID
7a909b25-3772-403e-a5fe-e4a040293fb7
Labeler
CMP Pharma, Inc.
DailyMed page updated
2022-10-15
Label revision
10/2022
Renal-function method
CrCl, mL/min; exact 30 mL/min is not assigned in the printed dosage bands
Source date/version
10/2022
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
1d69c7c0c323801e8d7d663971996397ce9840c14f5ebac023e5d1ca19dbf15a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - TADLIQ

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · TADLIQ oral suspension for WHO Group 1 pulmonary arterial hypertension; not as-needed erectile dysfunction or a fixed-combination tadalafil product.

Renal method: CrCl, mL/min; exact 30 mL/min is not assigned in the printed dosage bands
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For PAH, the source starts patients with CrCl 51-80 or 31-50 mL/min at 20 mg once daily, with an increase to 40 mg once daily according to tolerability. Severe impairment is an avoidance setting; the dosage section prints CrCl <30 mL/min and hemodialysis, and the renal-use section advises avoidance in severe impairment. Dialysis does not meaningfully correct exposure.

The printed bands do not assign exactly 30 mL/min. No boundary is filled in here. These are PAH instructions, not an as-needed erectile-dysfunction schedule. The suspension is 20 mg/5 mL: the source lists 5 mL for 20 mg and 10 mL for 40 mg.

RDM54-rxlist-tadalafil-tadliq-pah-a6bdce8f3e-C1 · Source locator: Dosage and Administration; Renal Impairment; selected Warnings and Precautions

Source-specific limits

Selected sections only. Source mirror and underlying label are not independent confirmations.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/tadliq-drug/
Retrieved
2026-09-09
Renal-function method
CrCl, mL/min; exact 30 mL/min is not assigned in the printed dosage bands
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
1d69c7c0c323801e8d7d663971996397ce9840c14f5ebac023e5d1ca19dbf15a

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/tadliq-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
a92b2e48a2156bebe8f90054a1d8114d2b14f10c71923852880229d788fd7751
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report